7 results about "Colonic mucosa" patented technology

The application of mussel polysaccharide in preparation of a medicine for regulating the intestine-liver axis to treat alcoholic liver injury belongs to the technical field of natural products and biological medicine. The method takes mussel polysaccharide as an active ingredient, and divides experimental mice into a normal control group, an alcoholic liver injury model group, a positive control group and mussel polysaccharide low-, medium- and high-dose groups (60, 120 and 180 mg / kg / day), and continuously intervenes for 4 weeks. The results show that the mussel polysaccharide can significantly reduce liver function indexes such as ALT and AST, improve TC, TG, LDL-C, HDL-C related blood lipid disorders, protect the colon mucosal barrier, regulate the intestine-liver axis homeostasis, effectively reduce alcohol-induced liver fatty degeneration, inflammatory infiltration and oxidative stress injury, and the effect shows obvious dose dependence. The mussel polysaccharide is safe, non-toxic, economical in source, simple in intervention method and strong in repeatability, and provides a new way for the development of functional food and liver protection products for preventing and treating alcoholic liver injury.

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

This invention discloses a probiotic composite hydrogel with colonic mucosal targeting function, its preparation method, and its applications. The hydrogel uses thiolated sodium alginate and catechin-modified chitosan as a matrix, constructing a dual network structure through calcium ion-mediated ionic crosslinking and covalent crosslinking to encapsulate Bifidobacterium bifidum Z29-2. The hydrogel exhibits excellent mucosal adhesion and intestinal retention capacity, demonstrating good probiotic protection and sustained-release characteristics in simulated gastrointestinal fluid. The microspheres with 2.5% calcium ion crosslinking exhibit regular morphology and dense structure, significantly prolonging intestinal retention time. The composite hydrogel constructed in this invention combines protective, targeting, and sustained-release functions, can regulate mucin glycosylation, and enhance the intestinal barrier, showing promising application prospects in the field of intestinal microecological therapy.

The application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis belongs to the field of biomedical technology. This invention addresses the limitations of existing treatments for inflammatory bowel disease (IBD), which suffer from limited efficacy, significant side effects, and difficulty in targeting and repairing the intestinal immune barrier. It provides the application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis. This recombinant ultra-high molecular weight hyaluronic acid can activate the intestinal IgA-producing immune network, regulate inflammation-related genes, and repair the physical and immune barriers of the colonic mucosa, thus exhibiting a superior protective effect against colitis compared to conventional hyaluronic acid, providing a new candidate drug for the treatment of IBD.

The application relates to the technical field of medical data processing, in particular to a Crohn's disease prediction method based on metabolism-immunity, which comprises a collection module, a peripheral blood and a colon mucosa biopsy sample of a subject are collected to obtain data; a prediction module, a Treg cell function index is calculated according to the data, a fatty acid oxidation pathway activation index is calculated; a Crohn's risk index is calculated and a result is output; the application takes an ALA-CPT1A / CD36-FAO-Treg cell function regulation axis as a core, quantitatively couples alpha-linolenic acid concentration, expression of a core molecule of an FAO pathway, a Treg cell function comprehensive index and a clinical correction factor, and sequentially constructs: a Treg cell function comprehensive index reflecting an immune core state; an FAO pathway synergistic activation index reflecting a regulation effect of metabolism on immunity; and prediction is realized in combination with the Treg cell function comprehensive index, the FAO index and clinical correction.

This application discloses an information-based planning and evaluation system for the treatment of active ulcerative colitis, belonging to the field of planning and evaluation technology. By analyzing the state data of food and drugs after they pass through the digestive tract, and calculating sharpness and residue load, it quantifies the potential mechanical stimulation or burden that different foods and drugs may cause to the fragile and damaged colonic mucosa. It provides a more sensitive and accurate quantitative tool by automatically extracting microscopic feature data from endoscopic images. In addition to predicting drug efficacy, it also predicts mucosal healing trends under specific food patterns. Regarding drug recommendations, it obtains a drug recommendation list through weighted integration using machine learning models and the aforementioned prediction results. For dietary advice, it combines association rule mining and Bayesian networks to obtain specific food pattern suggestions, improving the targeting and patient suitability of dietary management, and enhancing the transparency and safety of clinical decision-making.